Qure.ai is transforming routine medical imaging into early disease detection at unprecedented scale. Processing nearly 1,000 patients per hour across 105 countries, the startup has made preliminary radiology reports at India’s AIIMS and CMC Vellore AI-powered often flagging diseases physicians weren’t even looking for. In this conversation, Vikas Dandekar speaks with Prashant Warier Co-founder & CEO, Ankit Modi, Founding Member and Chief Product Officer and Preetham Putha, Founding Member and Chief AI Officer about how Qure.ai is reimagining diagnostics. Their breakthrough includes risk-scoring algorithms that detect high-risk lung nodules on standard chest X-rays, achieving a 54% CT-confirmed malignancy rate. From TB screening programs in Mumbai. where their tools uncovered 35% more cases for lung cancer detection in US hospitals, Qure.ai now holds 19 FDA clearances and WHO endorsement for autonomous AI diagnosis. Founded in 2016 and trained on over 1.5 billion anonymized images, Qure.ai has published clinical evidence in The Lancet and Nature. With current revenues of ₹200 crore, the company is targeting profitability within two years while scaling toward its ambition of impacting 1 billion lives by 2030.
See omnystudio.com/listener for privacy information.
